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Algorithm in Pulmonary Arterial Hypertension
Robyn J. Barst, MD,* J. Simon R. Gibbs, MD,† Hossein A. Ghofrani, MD,‡ Marius M. Hoeper, MD,§
Vallerie V. McLaughlin, MD, Lewis J. Rubin, MD,¶ Olivier Sitbon, MD,# Victor F. Tapson, MD,**
Nazzareno Galiè, MD††
New York, New York; London, United Kingdom; Giessen, and Hannover, Germany; Ann Arbor, Michigan;
La Jolla, California; Clamart, France; Durham, North Carolina; and Bologna, Italy
Uncontrolled and controlled clinical trials with different compounds and procedures are reviewed to define the risk-
benefit profiles for therapeutic options in pulmonary arterial hypertension (PAH). A grading system for the level of
evidence of treatments based on the controlled clinical trials performed with each compound is used to propose an
evidence-based treatment algorithm. The algorithm includes drugs approved by regulatory agencies for the treatment
of PAH and/or drugs available for other indications. The different treatments have been evaluated mainly in idio-
pathic PAH, heritable PAH, and in PAH associated with the scleroderma spectrum of diseases or with anorexigen use.
Extrapolation of these recommendations to other PAH subgroups should be done with caution. Oral anticoagulation is
proposed for most patients; diuretic treatment and supplemental oxygen are indicated in cases of fluid retention and
hypoxemia, respectively. High doses of calcium-channel blockers are indicated only in the minority of patients who
respond to acute vasoreactivity testing. Nonresponders to acute vasoreactivity testing or responders who remain in
World Health Organization (WHO) functional class III, should be considered candidates for treatment with either an
oral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist. Continuous intravenous administration of
epoprostenol remains the treatment of choice in WHO functional class IV patients. Combination therapy is recom-
mended for patients treated with PAH monotherapy who remain in WHO functional class III. Atrial septostomy and
lung transplantation are indicated for refractory patients or where medical treatment is unavailable. (J Am Coll
Cardiol 2009;54:S78–84) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.017e
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bn 1891, Ernst von Romberg, a German physician, described
n autopsy subject as having “pulmonary vascular sclerosis”;
owever, it is only since 1995 with the introduction of
ntravenous epoprostenol that disease-specific targeted medical
herapies for pulmonary arterial hypertension (PAH) have
ecome available. Furthermore, significant advances in the
reatment of PAH have occurred during the past 15 years.
urrently 9 medical therapies have either received regulatory
pproval or are under regulatory review. These agents target
he prostacyclin pathway, the nitric oxide pathway, and the
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Manuscript received February 6, 2009, accepted April 15, 2009.ndothelin pathway. Combination trials have demonstrated
dditive or synergistic benefit by targeting 2 or all 3 of these
athways.
Until the 1980s, attempts to reduce pulmonary arterial
ressure were performed with nonselective (pulmonary and
ystemic) vasodilators. Favorable and sustained results were
onvincingly shown only with the use of high doses of
alcium-channel blockers (CCBs) and only in the minority of
atients who responded to acute vasoreactivity testing (1–6). In
ddition, oral anticoagulant treatment was considered effective
n the basis of retrospective or uncontrolled studies (1,7–9). In
he 1990s, treatment with continuous IV administration of
poprostenol was shown in 3 nonblinded randomized clinical
rials (RCTs) to improve symptoms, exercise capacity, and
emodynamic status in PAH and to improve survival in
diopathic pulmonary arterial hypertension (IPAH)/heritable
ulmonary arterial hypertension (HPAH) (10–12). During
hat period, favorable results of several uncontrolled series of
AH patients who underwent atrial septostomy or lung
ransplantation were also reported (13–16).
Twenty RCTs with 9 new compounds as monotherapy have
een completed in PAH patients (10–12,17–31). In addition,
RCTs testing combinations of agents (e.g., endothelin-
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June 30, 2009:S78–84 Medical Treatmenteceptor antagonists [ERAs] and phosphodiesterase [PDE]-5
nhibitors, or prostanoid and ERA or PDE-5 inhibitors) have
een completed (32–37). Approximately 5,000 patients have
articipated in these studies aimed at developing effective
reatments for PAH.
The conclusions derived from clinical trials over the past 15
ears have provided us with an evidence-based treatment
trategy. The purpose of the present report is to review the
CTs performed in PAH and to propose an evidence-based
pdated treatment algorithm that incorporates currently avail-
ble therapies. This algorithm can be used worldwide, subject
o the availability of specific drug therapies.
ncontrolled Clinical Studies in PAH
nticoagulants. The evidence for favorable effects of oral
nticoagulant treatment in patients with IPAH, HPAH, or
AH associated with anorexigens is based on retrospective
nalyses from 7 studies, of which 5 were positive and 2 were
egative (1,7–9). The survival of anticoagulated patients se-
ected on the basis of clinical judgment was improved, as
ompared with a concurrent population that was not treated
ith oral anticoagulants. Three-year survival improved from
1% to 49% in the series reported by Fuster et al. (7); and the
- and 5-year survival rates increased from 31% to 47% and
rom 31% to 62%, respectively, in the series reported by Rich
t al. (1). These studies were not randomized, and one can
rgue that the lower survival of the control groups could be
elated to comorbidity that precluded the use of anticoagula-
ion in the untreated patients. In addition, only IPAH,
PAH, and anorexigen-related PAH patients were included
n the studies. In recent RCTs, approximately 70% of patients
ere treated with oral anticoagulants (10–12,17–37). Interest-
ngly, the highest prevalence of oral anticoagulant treatment
as seen in the trials involving mainly IPAH and HPAH
atients in World Health Organization (WHO) functional
lass III and IV, whereas the lowest prevalence was observed in
trial of patients with scleroderma. It should be emphasized
hat there is no evidence of any difference in the efficacy of oral
nticoagulant therapy on the basis of functional class severity.
iuretics, digoxin, and oxygen. The symptomatic and
linical benefits of diuretic treatment in right heart failure
reclude the need for controlled trials to demonstrate efficacy
n PAH. In recent RCTs with new treatments, approximately
0% to 70% of patients were treated with diuretics (38,39).
he lack of trials with specific classes of diuretics in PAH and
ndividual variability in responses leave the choice of the type
nd dose of drug to be used in individual cases to the
xperience of the physician.
Short-term intravenous (IV) administration of digoxin in
PAH produces a modest increase in cardiac output and a
ignificant reduction in circulating norepinephrine (40); no
ata are available on the effects of long-term treatment.
ccordingly, the use of digitalis in PAH patients is based
rimarily on the judgment of the physician rather than on
cientific evidence of efficacy. Digoxin was administered to Epproximately 25% to 50% of pa-
ients in recent RCTs in PAH
38).
No consistent data are currently
vailable on the effects of long-
erm oxygen treatment in PAH.
lthough improvement in pulmo-
ary hypertension (PH) with low-
ow supplemental oxygen has
een reported in some PAH pa-
ients (41), this has not been con-
rmed in controlled trials. In a
ontrolled study in patients with
isenmenger syndrome, nocturnal
xygen therapy had no effect on
ematologic variables, quality of
ife, or survival (42); in contrast, a
revious study suggested increased
urvival (43).
CBs. Favorable clinical and
rognostic effects of high doses of
ral CCB drugs in acutely vasore-
ctive patients with IPAH have
een shown in single-center, non-
andomized, uncontrolled studies
1–6). In these studies, the control
roup consisted of nonresponders,
ho might have a poorer prognosis, as compared with acutely
asoreactive individuals (3). Furthermore, the demonstration of
consistent reduction of pulmonary artery pressure by acute
harmacologic testing in vasoreactive patients raises ethical
uestions concerning the appropriateness of performing
lacebo-controlled clinical trials in these patients.
A definition of “a positive acute vasoreactive response” to
redict long-term response with high-dose oral CCBs was
roposed at the 3rd World Symposium on Pulmonary Hyper-
ension in 2003 (5). With this definition—reduction of mean
ulmonary arterial pressure 10 mm Hg to reach a mean
ulmonary arterial pressure40 mm Hg with a normalized or
ncreased cardiac output with acute pulmonary vasodilator
hallenge with either inhaled nitric oxide or intravenous
poprostenol—10% of IPAH patients have a positive acute
asoactive response.
Favorable results of long-term administration of high doses
f oral CCBs have also been shown in children with IPAH
4,6). In contrast, the effects of high-dose CCBs on associated
orms of PAH have not yet been clearly demonstrated (41).
cute vasodilator testing is recommended for all PAH pa-
ients, even though patients with IPAH and anorexigen-
nduced PAH are more likely to respond. Furthermore, al-
hough functional class IV patients are less likely to respond
han functional class II and III patients, some functional class
V patients might respond favorably to acute vasodilator testing
nd might benefit from CCBs; however, it is recommended
hat these patients be evaluated in a specialized PH center.
Abbreviations
and Acronyms
CCB  calcium-channel
blocker
ERA  endothelin receptor
antagonist
ETA  endothelin receptor A
ETB  endothelin receptor B
HPAH  heritable
pulmonary arterial
hypertension
INR  international
normalized ratio
IPAH  idiopathic
pulmonary arterial
hypertension
IV  intravenous
PAH  pulmonary arterial
hypertension
PDE  phosphodiesterase
PH  pulmonary
hypertension
RCT  randomized
controlled trial
WHO  World Health
Organizationmpirical treatment with CCBs without a positive response
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Medical Treatment June 30, 2009:S78–84ith acute vasodilator testing using either inhaled nitric oxide
r IV epoprostenol is contraindicated (41).
urgical and interventional procedures. Lung transplan-
ation or atrial septostomy might be indicated in select patients
ho progress despite optimal medical therapy or for whom
edical therapy is not available. Lung transplantation and
trial septostomy are discussed in detail in another article in
his supplement (44).
ontrolled Clinical Trials in PAH
ynthetic prostacyclin and prostacyclin analogues. The
fficacy of continuous IV administration of epoprostenol (syn-
hetic prostacyclin) has been evaluated in 3 unblinded, con-
rolled clinical trials: 2 in IPAH/HPAH (10,11), and 1 in
AH associated with the scleroderma spectrum of diseases
12). Although IV epoprostenol improves symptoms, exercise
apacity, and hemodynamic status in both clinical conditions,
urvival was increased only in IPAH and HPAH.
Five RCTs with 3 prostacyclin analogues as monotherapy
ave been performed in PAH patients (19,45). The effects of
ontinuous subcutaneous administration of treprostinil were
ssessed in a pilot RCT in which the improvement in exercise
apacity was not statistically significant (45). In the 2 pivotal
CTs, improvements were reported in symptoms, exercise
apacity, and hemodynamic status (19). Continuous IV ad-
inistration of treprostinil seems to be safe and effective on the
asis of 2 small, open-label, uncontrolled studies in patients
ith PAH (46,47).
The orally active prostacyclin analogue beraprost was eval-
ated in PAH patients in 2 RCTs, 1 in Europe (20) and 1 in
he U.S. (23). In the first study, an increase in exercise capacity
as seen after 3 months. In the second, which lasted 12
onths, improvement in exercise capacity was observed at 3
nd 6 months but not thereafter (23). No hemodynamic
mprovements were observed in the 12-month study, and
linical events were reduced only at the 6-month evaluation.
Inhaled iloprost as monotherapy was evaluated in 1 RCT
hat enrolled patients with both PAH and chronic thrombo-
mbolic PH (21). Overall, this study showed an increase in
xercise capacity and improvement in symptoms, pulmonary
ascular resistance, and clinical events in PH patients. Contin-
ous IV administration of iloprost was shown to be effective in
small, open-label, uncontrolled series of patients with PAH
nd chronic thromboembolic PH (48).
ndothelin receptor antagonists. Nine RCTs using 1 of 3
RAs as monotherapy have been performed in PAH patients.
he orally active endothelin receptors A and B (ETA/ETB)
RA bosentan was evaluated in 4 RCTs in PAH patients
17,22,27,30,49), including 1 RCT performed in a cohort of
atients with the Eisenmenger syndrome (27) and 1 RCT
erformed in a cohort of patients with only mildly symptom-
tic PAH (30). Overall, bosentan improved exercise capacity,
unctional class, hemodynamic status, echocardiographic and
oppler variables, and time to clinical worsening
17,22,27,31,49). Small increases in the dose of warfarin might ae required to maintain therapeutic international normalized
atio (INR) when bosentan is coadministered with warfarin.
Sitaxsentan, an orally active ETA selective ERA, has been
ssessed in PAH patients in 2 RCTs, both of which demon-
trated improvement in exercise capacity (assessed by the
-min walk test) and hemodynamic status (25,28,50). In 1 of
he 2 studies (25), the primary end point (peak oxygen
onsumption as assessed by cardiopulmonary exercise testing)
as not statistically significant. Coadministration of sitaxsen-
an and warfarin requires the reduction of the warfarin dose up
o 80% to maintain a therapeutic INR, due to a drug–drug
nteraction.
Ambrisentan, an orally active ETA selective ERA, has been
valuated in 3 RCTs (29,51,52). Results showed improve-
ents in exercise capacity and clinical events that seem similar
o the results observed with the other 2 ERAs.
On the basis of the results of RCTs using ERAs, the
ncidence of elevated hepatic transaminases 3 times the
pper limit of normal seems to be approximately 10% with
osentan, approximately 4% with sitaxsentan, and approxi-
ately 2% with ambrisentan. The patient populations in the
arious RCTs differed, and these numbers should be consid-
red only as approximations and may not be comparable.
DE-5 inhibitors. Two RCTs with 2 different PDE-5
nhibitors have been performed in PAH patients (26,31). Used
s monotherapy, both sildenafil and tadalafil improved exercise
apacity and hemodynamic status in approximately 50% of
nrolled patients; tadalafil also improved clinical events (31).
The optimal agent for PAH monotherapy remains un-
lear.
ombination therapy. More recently, combination treat-
ent has been evaluated to address the multiple pathobiologic
echanisms present in PAH. The combination of oral bosen-
an and IV epoprostenol was investigated in 1 small study, with
nconclusive results (32). Five additional RCTs have evaluated
ombination therapy in PAH. The addition of inhaled iloprost
o background oral bosentan demonstrated improved hemo-
ynamic status and clinical events in 1 RCT (35); however,
hese results were not confirmed in an open trial (34). In
nother study, the addition of oral sildenafil to background IV
poprostenol demonstrated improved exercise capacity, hemo-
ynamic status, and clinical events; furthermore, in post hoc
nalysis, the addition of oral sildenafil to background IV
poprostenol increased survival versus IV epoprostenol alone
37). In the pivotal tadalafil RCT, approximately 50% of the
atients had oral tadalafil added to background oral bosentan;
n that study overall, tadalafil improved exercise capacity,
emodynamic status, and clinical events (31). Inhaled trepro-
tinil has also been studied as add-on therapy to either
ackground bosentan or background sildenafil; in both com-
inations, the addition of inhaled treprostinil improved exer-
ise capacity (36). These studies support the efficacy of com-
ination treatment in patients who remain symptomatic on
onotherapy. The optimal combination on the basis of overall
isk-benefit considerations remains unknown.
Although there seems to be an interaction between sildenafilnd bosentan (increased bosentan and decreased sildenafil
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June 30, 2009:S78–84 Medical Treatmentevels) (53), the clinical relevance of this is unclear. Similarly,
lthough the interaction between tadalafil and bosentan is less
han that between sildenafil and bosentan (i.e., tadalafil expo-
ure decreased with minimal changes in bosentan exposure)
54), the clinical relevance is also unknown. Tadalafil has also
een evaluated in the presence of ambrisentan, with no
linically relevant pharmacokinetic interactions reported (55).
here is no clinically relevant pharmacokinetic interaction
etween ambrisentan and sildenafil (56), with no dose adjust-
ent of ambrisentan or sildenafil recommended compared
ith administration of either drug alone. There is a minimal
nteraction reported between sitaxsentan and sildenafil, with no
hanges in sitaxsentan plasma concentrations in the presence of
ildenafil and only modest increases in sildenafil plasma con-
entrations (57). Overall, no dose adjustments have been
ecommended for patients treated with 1 of the aforemen-
ioned ERAs in combination with either sildenafil or tadalafil.
arly intervention. For functional class II or III patients, the
ole of early aggressive intervention (i.e., IV epoprostenol as
rst-line treatment), either as monotherapy or in conjunction
ith either a PDE-5 inhibitor and/or an ERA, remains
Amlodipine, diltiazem, 
nifedipine (B)
YES
ACUTE RESPONDER
WHO Class I-IV
Amlodipine, diltiazem, 
nifedipine (B)
Sustained response 
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Acute vasoreacti
(E/C f
Expert re
Supportive therapyOral anticoagulants (E/B) – IPAH/HPAH
Diuretics (E/A)
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Digoxin (E/C)
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Strength of 
Recommendation WHO Cla
A
Ambrisentan, Bos
Sildenafil
B Sitaxsentan, Tada
C
E/B
E/C
Not approved
Sequential com
PDE-5 I +
+ (B)
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Figure 1 PAH Evidence-Based Treatment Algorithm
Drugs within the same grade of evidence are listed in alphabetical order and not o
tries. Strengths of recommendations are defined in Table 1. *To maintain oxygen
rial hypertension; ERA  endothelin receptor antagonist; HPAH  heritable pulmon
intravenous; PAH  pulmonary arterial hypertension; PDE-5  phosphodiesterase typenknown. Although the first RCTs in PAH focused primarily
n functional class III and IV patients, results from a more
ecent RCT evaluating the efficacy of bosentan in only mildly
ymptomatic PAH patients support early intervention (30). In
ddition, prespecified subgroup analyses of the sildenafil,
adalafil, and ambrisentan RCTs did not show any significant
ifferences in the therapeutic efficacy of these drugs between
atients in WHO functional classes II and III (30). The
pparent lack of “catch-up” in placebo-treated patients sup-
orts early intervention in PAH (41). Future studies seem
arranted.
eneral comments on controlled clinical trials. Although
hese studies have similar designs, treatment duration, and end
oints, analyses of baseline WHO functional class and etiology
rofiles show substantial differences. Accordingly, comparisons
ight be misleading. Improvement of exercise capacity as
ssessed by the 6-min walk test has been observed in all of
hese studies, albeit to different degrees. In evaluating the
linical relevance of exercise capacity improvements, additional
lements, such as baseline functional class, effects on combined
linical events (e.g., hospital stays, mortality, rescue therapies),
Atrial septostomy (E/B) and/or
lung transplant (E/A)
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Medical Treatment June 30, 2009:S78–84nd hemodynamic effects, should be considered. As mentioned
reviously, a survival benefit has been demonstrated in only 1
ontrolled, third-party–blinded study of IV epoprostenol in
atients with severe IPAH/HPAH (11). Because, on the basis
f these results, IV epoprostenol is considered rescue therapy,
ubsequent RCTs assessing mortality as an end point could not
thically be performed. Furthermore, severely ill subjects re-
uiring IV epoprostenol treatment were excluded in recent
CTs, resulting in a low mortality in these study populations.
recent meta-analysis performed on all RCTs in PAH
atients published through October 2008 reports a 43%
ecrease in mortality and a 61% reduction in hospital stays in
atients treated with targeted therapies versus patients ran-
omized to placebo (39). These results, achieved after an
uality of Evidence, Net Benefit,nd Strength of R commendation
Table 1 Quality of Evidence, Net Benefit,and Strength of Recommendation
Variables Description
Quality of the evidence
Good Evidence is based on good randomized controlled
trials or meta-analyses.
Fair Evidence is based on other controlled trials or
randomized controlled trials with minor flaws.
Low Evidence is based on nonrandomized, case-
control, or other observational studies.
Expert opinion Evidence is based on the consensus of the carefully
selected panel of experts in the topic field.
There are no studies that meet the criteria for
inclusion in the published reports review.
Net benefit
Substantial
Intermediate
Small/weak
None
Conflicting
Negative
Strength of recommendation
A Strong recommendation
B Moderate recommendation
C Weak recommendation
D Negative recommendation
I No recommendation possible (inconclusive)
E/A Strong recommendation on the basis of
expert opinion only
E/B Moderate recommendation on the basis of
expert opinion only
E/C Weak recommendation on the basis of
expert opinion only
E/D Negative recommendation on the basis of
expert opinion only
elationship of Strength of the Recommendations Scale to Quality
Table 2 Relationship of Strength of the Recommendations Sca
Quality of Evidence Substantial Intermediate
Good A A
Fair A B
Low B C
Expert opinion E/A E/Bee Table 1 for definition of designations.verage treatment period of 14.3 weeks, support the efficacy of
he currently approved PAH treatments.
vidence-Based Treatment Algorithm
treatment algorithm based on a consensus of the PH
ommunity evaluating the clinical trials presented in this
eview is presented in Figure 1. The recommendations in this
uideline are based on a grading system in which the strength
f the recommendation results from the interaction of 2
omponents: the quality of the evidence, and the net benefit of
he therapy (Tables 1 and 2). Because treatments have been
valuated primarily in IPAH, HPAH, and PAH associated
ith scleroderma or anorexigen use, extrapolation of these
ecommendations to other PAH subgroups should be done
ith caution.
onclusions
he suggested initial approach after the diagnosis of PAH is to
reat patients with oral anticoagulant drugs if no contraindica-
ion exists, diuretics in cases of fluid retention, and supplemen-
al oxygen in cases of hypoxemia, even though RCTs with
hese compounds are lacking. Patients should be referred
ithout delay to centers experienced in acute vasoreactivity
esting and the treatment of pulmonary vascular diseases.
cute vasoreactivity testing should be performed in all patients
ith PAH, although patients with IPAH, HPAH, and PAH
ssociated with anorexigen use are the most likely to exhibit a
ositive response. Vasoreactive patients, as defined in the
receding text, should be treated with optimally tolerated doses
f CCBs; maintenance of response, defined as WHO func-
ional class I or II with near-normal hemodynamic status,
hould be confirmed by repeat right heart catheterization and
linical assessment after 3 to 6 months of treatment. Nonre-
ponders to acute vasoreactivity testing or responders who
emain in WHO functional class III should be considered
andidates for treatment with either a PDE-5 inhibitor or an
RA. Among prostanoids, treprostinil is administered subcu-
aneously, intravenously, or by inhalation; iloprost can be given
ntravenously or by inhalation; beraprost is administered orally,
nd epoprostenol is administered intravenously.
The choice of drug is dependent on a variety of factors,
ncluding the approval status, route of administration, side-
ffect profile, patient preference, and the physician’s experience
nd clinical judgment. Continuous IV epoprostenol remains
rst-line therapy for PAH patients in WHO functional class
V, because of its demonstrated survival benefit in IPAH/
idence and Net Benefits
Quality of Evidence and Net Benefits
Net Benefit
mall/Weak None Conflicting Negative
B D I D
C D I D
C I I D
E/C I I E/Dof Ev
le to
S
H
W
c
d
p
p
c
f
F
i
c
d
a
a
e
n
p
p
p
A
D
a
L
G
l
P
i
h
S
v
g
a
c
h
c
r
G
U
A
r
H
p
G
A
s
L
S
s
l
P
b
r
G
r
P
c
U
b
G
a
I
E
S
R
P
s
r
R
1
1
1
1
1
1
1
1
S83JACC Vol. 54, No. 1, Suppl S, 2009 Barst et al.
June 30, 2009:S78–84 Medical TreatmentPAH, with extrapolation to associated PAH patients in
HO functional class IV. Combination therapy should be
onsidered for patients who fail to show improvement or who
eteriorate with monotherapy. The goal in treating PAH
atients is to improve WHO functional class III and IV
atients to functional class I or II and to improve all functional
lass II patients to functional class I or at least to maintain
unctional class II in patients presenting in that functional class.
inally, both atrial septostomy and lung transplantation are
ndicated in carefully selected patients for refractory PAH or in
ases where medical treatments are unavailable. These proce-
ures should be performed only in experienced centers.
Major therapeutic advances for PAH patients have been
chieved in the last decade; however, none of the currently
pproved therapies represents a cure for this progressive dis-
ase. The search for such treatments continues, with promising
ew concepts arising from a better understanding of the
athobiology of pulmonary vascular diseases. Patients and
hysicians should be encouraged to foster such research by
articipating in RCTs conducted at specialized PH centers.
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